GENERAL

• Document Type: CREST
• Collection: STARGATE
• Document Number (FOIA) /ESDN (CREST): CIA-RDP96-00788R001500110003-2
• Release Decision: RIFPUB
• Original Classification: K
• Document Page Count: 6
• Document Creation Date: November 4, 2016
• Document Release Date: September 6, 2000
• Sequence Number: 3
• Content Type: NOTES

Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
1. (U) GENERAL
1.1 (S/CL-3/NOFORN) The objective of this effort is to
investigate a particular aspect of the psychoenergetic phenomena known
as remote viewing that has potential military intelligence
application. Coordinate Remote Viewing (CRV) is a staged technique
which utilizes coordinates to facilitate acquisition of a remote
viewing target.
1.2 (S/CL-3/NOFORN) Major goals are the determination if CRV
technology can be successfully transferred to INSCOM personnel with a
corresponding increase in the reliability of a remote viewer.
2. (U) SPECIFIC TASK
2.1 (S/CL-3/NOFORN) Train army personnel in CRV Stages III and
2.1.1 (S/CL-3/NOFORN) Initiate training at the highest skill
level (CRV Stage) of the trainee.
2.1.2 (S/CL-3/NOFORN) Training for each CRV stage will normally
be divided into three two week working sessions. The session dates
will be mutually agreed to by SRI and INSCOM.
2.1.3 (S/CL-3/NOFORN) After successful completion of CRV Stage
III, schedule the trainee to begin CRV Stage IV.
2.2 (U) Determine the potential of the trainee for further
training.
3. (U) SECURITY
Military security requirements in the performance of this contract
shall be maintained in accordance with DD Form 254 attached hereto.
The highest classification involved in the performance of this
contract is SECRET- NO FOREIGN DISSEMINATION.
4. (U) DELIVERABLES: The contractor will provide the following.
4.1 (S/CL-3/NOFORN) State-of-the-Art CRV training.
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
Written
week evaluation of
4.2 (U) Progrethe report copies) :
on.
trainees progress at completion 4.3 (U) Final Report:
4.3.1 (U) A final report in three copies will be furnished
within 30 days after completion of each training stage.
4.3.2 (U) Report will include a summary of the training
presented; an evaluation of the trainee's ability to understand the
training; and a summary of the trainee's accomplishments during the
training period.
4.3.3 (S/CL-3/NOFORN) Report should also include an evaluation of
the trainee's future remote viewing capabilities, and a recommendation
concerning further training.
5. (S/CL-3/NOFORN) POST TRAINING ACCESS: After the completion of
to prgram
trained training
each training to personnel
INSCOM personnel the
will in
will l have reasonable access further evaluation of CRV.
6. (U) SPECIAL REQUIREMENTS
6.1 (U) Use of human subjects
(a) (U) The following definitions are used:
(1) (U) At risk means that the human subject may be exposed
to the possibility of harm - physical, biological, psychological,
sociological, or other as a consequence of an act or omission that
goes beyond the application of those established and accepted methods
or procedures which are in his best interests, or that increases
ordinary risks of daily life, including the recognized risks inherent
in his chosen occupation or field of service.
(2) (U) Human subject means any human being who, knowingly
or unknowingly, is subjected to an act or omission, whether at risk or e to not, the object of which is under contribute
scopenoflthis contra gained as
a part of work to be performed
(b) (U) The contractor, before undertaking to perform any
study involving human subjects, whether at risk or not, shall insure
that the following minimum conditions are complied with:
(1) (U) The proposed study has been reviewed and approved by
a committee meeting the requirements set forth in Chapter 46 of Title
45 of the Code of Federal Regulations.
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
(2) (U) The number of human subjects used will be kept to
the minimum number that will reasonably achieve the required results.
(3) (U) The study must be such as to contribute
significantly to scientific knowledge and have reasonable prospects of
yielding important results essential to an Army research program.
(4) (U) The study will be conducted only by persons
possessing the requisite scientific qualifications. The highest
degree of skill and care will be required during all stages of study
of persons who conduct or assist in the study.
(5) (U) The subject will be informed that at any time during
the course of his participation he has the right to revoke his consent
and withdraw from participation without prejudice to himself.
(6) (U) Participation by subjects will be immediately
terminated if it subsequently appears that the risk to the subjects is
significantly greater than anticipated at the time review and approval
was granted.
(7) (U) There shall be no greater intrusion into the privacy
of the human subject than is absolutely necessary for the conduct of
the study involved. Except for the submission of reports and other
data required by this contract, any information obtained about human
subjects as a result of participation shall be held as confidential as
the law allow.
(8) (U) The study will be conducted so as to avoid all
unnecessary physical or mental suffering or injury.
(9) (U) No study will be conducted if there is any inherent
reason to believe that death or disabling injury is likely to occur.
Sufficient animal or laboratory experiments, or other evaluations,
must have been completed to give assurance of acceptable risks prior
to the use of human subjects.
(10) (U) The degree of risk to be taken will never exceed
that which is justified by the benefit to the subject and/or the
humanitarian importance of the knowledge to be gained.
(11) (U) A physician will be responsible for the medical
care of subjects. Even if not the project leader, the physician will
have authority to terminate the study at any time that he believes
death, injury or harm is likely to result.
(12) (U) Proper preparations will be made, and adequate
facilities provided to protect the subject against all foreseeable
possibilities if injury, disability or death. This includes but is
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
not limited to hospitalization and medical treatment as may be
required. In addition, all apparatus and instruments necessary to
deal with likely emergency situations will be available.
(13) (U) Human subjects will have no physical or mental
conditions which will make participation more hazardous for them than
it would be for normal healthy persons, unless such condition is a
necessary prerequisite for the particular study involved. In any such
case, the use of human subjects with such pre-existing conditions must
have been specifically described and justified in the scope of the
work to be performed under this contract.
(14) (U) The scientifically qualified person conducting the
study, and each member of his research team, will be prepared to
terminate the subject's participation at any stage if he has reason to
believe, in the exercise of the good faith, superior skill, and
careful judgment required of him, that continuation is likely to
result in injury, disability, or death to the human subject.
(c) (U) The contractor, before permitting any person to
participate as a human subject, whether at risk or not, shall insure
that the following minimum conditions are complied with:
(1) (U) Legally effective informed consent will be obtained
by adequate and appropriate methods in accordance with the provisions
of this clause.
(2) (U) All consent must be voluntary. It must be the
knowing consent of the individual or his legally authorized
representative, so situated as to be able to exercise free power of
choice without there having been any use of force, fraud, deceit,
duress, constraint, coercion, or lawful or improper inducement. The
elements of information necessary to such consent include:
(i) (U) A fair explanation of the procedures to be followed,
and their purposes, including identification of any procedures which
are experimental.
(ii) (U) A description of any attendant discomforts or risks
reasonably to be anticipated.
(iii) (U) A description of any benefits reasonably to be
anticipated.
(iv) (U) A disclosure of any appropriate alternative
procedures that might be advantageous to the subject.
(v) (U) An offer to answer any questions concerning the
procedure.
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
(vi) (U) An instruction that the subject is free to revoke
his consent and to discontinue participation at any time without
prejudice to himself.
(d) (U) Exculpatory language through which the subject is
made to waive, or appear to waive, any of his legal rights, including
any release from liability for negligence, is prohibited.
(e) (U) Prior consent by a subject or his legally authorized
representative shall be obtained in all cases. Such consent shall be
in writing whenever it is reasonably possible to do so. The consent
form may be read to the subject or his legally authorized
representative, but in any event he or his legally authorized
representative must be given adequate opportunity to read it and to
ask questions they might have.
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2
This consent form should then be signed by the subject or his legally
authorized representative and by a witness not directly involved in
the study. Oral consent may be used only when it has been
specifically described and justified in the scope of the work to be
performed under this contract or approved in writing by the
contracting officer. When so authorized and used, oral consent is
subject to all the same standards as apply to written consent, except
that the signature of the subject or his legally authorized
representative is not required.
(f) (U) Prior to conduct of the study, the contractor shall
submit for approval to the contracting officer's representative a
detailed description of the means by which informed consent will be
obtained, to include any forms to be used. Upon completion of the
study, the contractor will submit to the contracting officer's
representative a detailed report demonstrating compliance with
paragraph (c), to include copies of the written consent if such was
obtained.
(g) (U) The contractor shall not undertake to conduct either
the clinical pharmacology or clinical trails of an investigational
drug unless this contract contains the clause entitled "Clinical Study
of Investigational Drugs."
(h) (U) Prisoners of war will not be used under any
circumstances.
6.2 (U) DOD Directive 5240.1-R governing experimentation on
human subjects will be followed by the contactor. Informed consent of
all subjects will be obtained in writing in accordance with the
guidelines issued by the Department of Health, Education and Welfare.
All persons participating as human subjects, as defined in paragraph
6.1 above shall be known to possess the abilities and qualities which
will be observed and analyzed during the conduct of this contract.
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110003-2